With More Regional Headquarters And R&D Centers Moving to Shanghai, Salary And Jobs Increasing - Survey
This article was originally published in PharmAsia News
Recruitment consultant Robert Walter’s Global Salary Survey sees salaries increasing in China’s pharma sector as MNCs continue to ramp up operations in Asia.
You may also be interested in...
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.